Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • After 11 years, Dr...

    After 11 years, Dr Reddys Lab gets Chinese regulator nod for generic Clopidogrel

    Meghna A SinghaniaWritten by Meghna A Singhania Published On 2019-04-24T12:06:30+05:30  |  Updated On 24 April 2019 6:36 AM GMT
    After 11 years, Dr Reddys Lab gets Chinese regulator nod for generic Clopidogrel

    Hyderabad: After a decade long wait, Dr Reddy's Laboratories (Dr Reddys) has finally bagged the approval from the Chinese regulator for its anti-blood clotting drug Clopidogrel. According to a recent media report, the Chinese regulator has shown a green flag to the drug, which is expected to land up in sales worth over Rs 11175 crore (USD 1.6 billion).


    As per a recent report in Business Standard, DRL received approval for generic Clopidogrel earlier this month. The drug is indicative of preventing blood clotting primarily and acts against cardiovascular issues. Clopidogrel, sold under the trade name Plavix among others, is an antiplatelet medication used to reduce the risk of heart disease and stroke in those at high risk.


    Presently, the drug is undergoing generic equivalent assessment (China requires drugmakers to conduct bioequivalence studies).


    Also Read: Dr Reddys launches Tadalafil tablets for treating erectile dysfunction


    Prior to this in 2012, DRL had launched generic Clopidogrel in the United States market along with its partner Mylan. The move came in following the expiry of patent for Sanofi-Aventis' Plavix, one of the best selling drugs in the US. During the patent period, the drug approximately had an annual sale of around USD 6.7 billion.


    According to Edelweiss analyst, DRL has seven to eight products lined up for approval from the Chinese drug regulator and it expects to increase the number of filings.


    “DRL is the largest international generic pharmaceutical company in China with presence across all provinces. In FY18, DRL clocked around $100 million sales from 8-10 products with sales accounted for in its joint venture (JV), Kunshan Rotam Reddy (DRL owns 51.3 per cent interest),” Edelweiss told Business Standard. The Joint Venture has a sales and marketing team covering 5000 hospitals spread over China.


    It is learnt through the media report that the launch of the formulation will take a while and the move would be DRL's biggest product in China concerning market potential.

    As per analysts, it takes around seven to eight years in China to receive approvals. However, as part of some friendly market reforms which will expedite the generic approval timelines, the Government is looking at speeding up the procedure. Thus, approvals for companies from outside China has increased in recent time.


    After the US, China is reportedly the world’s second-largest single country pharma market and according to estimates around 25 per cent of the drugs by value to Chinese hospitals are supplied by companies outside of the country.

    anti blood clot drug blood clotting drug Cardiovascular china Chinese drug Chinese drug regulator Chinese market clopidogrel Dr Reddy's Dr Reddy's Laboratories Dr Reddy's Labs Dr Reddys Lab Edelweiss generic heart attack heart disease heart problem heart stroke Hyderabad Mylan pharma pharma news pharma news india Plavix Sanofi 
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      3.36% of about 82,600 drugs samples found to be substandard

      3.36% of about 82,600 drugs samples found to be substandard

      Apollo medical centre in Oman granted hospital status

      Apollo medical centre in Oman granted hospital status

      Aurobindo Pharma receives USFDA approval to manufacture ADHD drug

      Aurobindo Pharma receives USFDA approval to manufacture ADHD drug

      Calcutta HC sets aside Centers decision for strategic sale of Bengal Chemicals

      Calcutta HC sets aside Center's decision for strategic sale of Bengal Chemicals

      FDA seizes unlicensed medical devices worth over Rs 1 crore from GT Hospital

      FDA seizes unlicensed medical devices worth over Rs 1 crore from GT Hospital

      Ipca Lab Conferred With the CARE Award

      Ipca Lab Conferred With the CARE Award

      View All

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 27 May 2022 6:45 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
      verify here.

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
      X
      X